Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.

Andres J YarurAlexandra BrussSnehal NaikPoonam Beniwal-PatelCaroline FoxAnjali JainBrandon BerensAmir PatelRyan UngaroBayda BahurMarla DubinskyDaniel J Stein

Published in: Digestive diseases and sciences (2019)

Vedolizumab concentrations during induction were associated with endoscopic remission at week 52. Interventional studies looking into improved efficacy with higher drug exposure are warranted.

Keyphrases

ulcerative colitis
ultrasound guided
patients with inflammatory bowel disease
disease activity
systemic lupus erythematosus
case control
emergency department